Jason Hannon has today taken up his role as chief executive at medical device company Mainstay Medical.
Mr Hannon, who was appointed last month, has also been appointed as a director of the company.
Mainstay Medical, which is quoted on the Irish Stock Exchange, is looking to bring to market its ReActiv8-B system, which treats chronic back pain.
Mr Hannon joins Mainstay from NuVasive, where he was president and chief operating officer.
"Mainstay has pioneered a new approach to treating chronic low back pain which seeks to help the body repair itself rather than merely masking pain," Mr Hannon said.
"ReActiv8 is aimed at providing a new therapy for the large number of patients for whom other treatments have failed. I look forward to working with the team to maximise the potential of ReActiv8 globally and build on Mainstay's technology platform," the new CEO added.
